Established during the heyday of the dot,com era, to achieve Publicly traded status, early in 2006, AngioGenex, Inc. had done a reverse merger with dot.com shell eClic and took a single SBIR Phase I in 2010. The firm operates as a biopharmaceutical company engaging the development and commercialization of a novel platform of anti-proliferative drugs for the treatment of cancer and maular degenerationThe firm had been using a promising, exclusively licensed technology (Id platform) from Memorial Sloan Kettering Cancer Center, New York, NY to work on anti-cancer drugs that block tumor-associated blood vessel formation, or angiogenesis. The AngioGenex Inc., pipeline of anti-cancer drug candidates includes: Small organic molecules for treatment of cancer (AGX51 and related molecules AGX1053, a targeted oligonucleotide. Monoclonal antibody (mAb). Clinical development based on synergy with widely prescribed taxanes like paclitaxel (Taxol) providing a rapid and relatively inexpensive development path for anti-Id agents. Use monoclonal antibodies of Id for development of highly sensitive assays for blood and tissue suitable for early detection of tumors and to detect recurrence of disease. AngioGenex, Inc. is engaged in the discovery and development of drugs that target regulators of gene transcription. The Companys lead clinical candidate, Idantirx/AGX51, was deisgned tolower the concentration of Id -inhibitor of differentiation proteins in cancer cells. The Id genes and proteins are not normally present in adult tissues unless pathologic conditions such as cancer are present. AngioGenex developed a diagnostic test to quantitate Id proteins in blood and used it to help select patients and to monitor response in clinical studies with Idantirx in cancer patients. The Company also has used Id technology for the discovery and development of anti-cancer drugs that block tumor-associated blood vessel formation, or angiogenesis
